Reaction

Oral Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,862 reports · 112 co-occurring drugs

As of the last recalculation, Oral Infection appears in 3,862 FAERS reports alongside 112 co-occurring drug terms. The strongest observed disproportionality signal is ALENDRONATE SODIUM (PRR 35.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Alendronate Sodium	564	35.1	35.3
Diphenhydramine Hydrochloride Capsule, Liquid Filled	51	13.0	13.1
Human Immunoglobulin G	48	12.7	12.7
Risedronate Sodium	69	12.2	12.2
Ciclesonide	21	8.3	8.4
Chlorhexidine Gluconate	14	8.3	8.3
Bimekizumab	29	7.4	7.4
Clindamycin Phosphate	45	7.3	7.3
Bicalutamide	19	6.7	6.8
Adrenalinum	50	6.6	6.6
Infliximab-Dyyb	34	6.3	6.3
Nystatin Ointment	30	6.2	6.2
Nystatin Cream	30	6.2	6.2
Clindamycin	32	6.1	6.1
Nystatin	30	6.0	6.0
Exemestane	23	5.8	5.8
Amoxicillin	79	5.7	5.7
Diphenhydramine	65	5.6	5.6
Voriconazole Injection	21	5.2	5.2
Epinephrine	61	5.1	5.1
Zoledronic Acid	37	5.0	5.0
Trazodone Hydrochloride	14	4.8	4.8
Desoximetasone	17	4.8	4.8
Dexamethasone Sodium Phosphate	9	4.8	4.8
Doxyclycline Hyclate	15	4.8	4.8
Vitamin E	27	4.7	4.7
Diphenhydramine Hydrochloride	138	4.6	4.6
Fulvestrant	28	4.6	4.6
Benzonatate	14	4.6	4.6
Lidocaine	48	4.5	4.5
Voriconazole	25	4.5	4.5
Zinc Gluconate	21	4.3	4.3
Anastrozole	29	4.3	4.3
Losartan Potassium And Hydrochlorothiazide	9	4.2	4.2
Amoxicillin And Clavulanate Potassium	21	4.2	4.2
Denosumab	150	4.1	4.1
Dextrose	10	4.1	4.1
Prochlorperazine Maleate	7	4.1	4.1
Raloxifene Hydrochloride	11	4.1	4.1
Dextrose Monohydrate	10	4.0	4.0
Dronabinol	6	4.0	4.0
Letrozole	45	4.0	4.0
Cyclobenzaprine	36	3.9	3.9
Buspirone Hydrochloride	8	3.9	3.9
Voclosporin	6	3.7	3.7
Oxycodone And Acetaminophen Tablets	8	3.6	3.6
Goserelin	9	3.6	3.6
Conjugated Estrogens	38	3.5	3.5
Cetirizine Hcl	6	3.5	3.5
Estrogens, Conjugated	38	3.5	3.5
Erythropoietin	13	3.4	3.4
Golimumab	52	3.3	3.3
Anakinra	10	3.3	3.3
Filgrastim	22	3.2	3.2
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	12	3.2	3.2
Naproxen Sodium, Pseudoephedrine Hydrochloride	12	3.1	3.1
Prochlorperazine	16	3.1	3.1
Certolizumab Pegol	66	3.1	3.1
Fluticasone Furoate And Vilanterol Trifenatate	20	3.0	3.0
Ixazomib	16	3.0	3.0
Fluticasone Propionate And Salmeterol	23	3.0	3.0
Thalidomide	20	2.9	2.9
Vilazodone Hydrochloride	5	2.9	2.9
Niraparib	12	2.9	2.9
Azacitidine	16	2.9	2.9
Buprenorphine Hydrochloride, Naloxone Hydrochloride	13	2.9	2.9
Linaclotide	14	2.8	2.8
Thiotepa	5	2.8	2.8
Apalutamide	6	2.8	2.8
Sunitinib Malate	20	2.8	2.8
Pomalidomide	52	2.7	2.8
Tofacitinib	92	2.7	2.7
Ocrelizumab	31	2.7	2.7
Brentuximab Vedotin	5	2.6	2.6
Secukinumab	77	2.6	2.6
Ozanimod Hydrochloride	4	2.6	2.6
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	2.6	2.6
Venetoclax	29	2.5	2.6
Conjugated Estrogens And Medroxyprogesterone Acetate	11	2.5	2.5
Abatacept	62	2.4	2.4
Mometasone Furoate And Formoterol Fumarate Dihydrate	7	2.4	2.4
Palbociclib	42	2.4	2.4
Ofatumumab	14	2.3	2.3
Lenalidomide	173	2.3	2.3
Upadacitinib	34	2.3	2.3
Cabozantinib	20	2.2	2.3
Natalizumab	75	2.2	2.2
Etanercept	237	2.2	2.2
Azacitidine For	7	2.1	2.1
Sarilumab	10	2.0	2.0
Peginterferon Alfa-2A	20	2.0	2.0
Ravulizumab	5	2.0	2.0
Obinutuzumab	6	2.0	2.0
Diclofenac Potassium, Film Coated	3	1.9	1.9
Diclofenac Potassium Tablets	3	1.9	1.9
Daratumumab	14	1.9	1.9
Belimumab	11	1.9	1.9
Alpelisib	3	1.9	1.9
Siponimod	3	1.8	1.8
Diroximel Fumarate	4	1.8	1.8
Polatuzumab Vedotin	3	1.7	1.7
Lenvatinib	10	1.6	1.6
Axicabtagene Ciloleucel	3	1.6	1.6
Ixekizumab	9	1.3	1.3
Osimertinib	7	1.2	1.2
Glycerin, Lidocaine	3	1.2	1.2
Docosanol	3	1.1	1.1
Hydrocodone Bitartrate	8	1.0	1.0
Abaloparatide	5	0.9	0.9
Guselkumab	6	0.9	0.9
Voxelotor	3	0.7	0.7
Valbenazine	3	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.